文献速递前列腺癌

前列腺癌诊断后继续使用5α-还原酶抑制剂与主动监测中重新分级及不良病理结果风险的关系:PASS研究

Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.
PubMed 文献 · J Urol · 2019-01-01

本研究基于多中心PASS队列,纳入2008至2016年诊断时为Gleason评分≤3+4且穿刺核心阳性比例<34%并至少接受一次监测活检的1009例前列腺癌患者,其中107例正在使用5α-还原酶抑制剂(5-ARI),902例从未使用。多因素分析显示,继续使用5-ARI与主动监测中重新分级风险无关(HR 0.81,p=0.31);5-ARI使用者接受根治性前列腺切除术(8% vs 18%,p=0.01)或任何根治性治疗(19% vs 24%,p=0.04)的比例更低;在167例接受根治性前列腺切除术的患者中,两组不良病理结果率未见差异。

要点

  • 前列腺癌诊断后继续使用5-ARI未增加主动监测中重新分级风险。
  • 5-ARI使用者接受根治性前列腺切除术或任何根治性治疗的比例更低。
  • 接受手术者中,5-ARI使用与不良病理结果无差异。

核心结论

  • 在前列腺癌初步诊断后继续使用5α-还原酶抑制剂与主动监测中重新分级风险无关。

研究设计与样本

  • 多中心前瞻性队列PASS研究,纳入2008至2016年1009例患者,其中107例使用5-ARI,902例从未使用。

主要发现

  • 多因素分析显示5-ARI使用与未使用组重新分级风险无差异(HR 0.81,p=0.31)。
  • 5-ARI使用者接受根治性前列腺切除术的比例为8%,未使用者为18%(p=0.01)。
  • 5-ARI使用者接受任何根治性治疗的比例为19%,未使用者为24%(p=0.04)。
  • 在167例接受根治性前列腺切除术的患者中,5-ARI使用者与未使用者不良病理结果率未见差异。

关键数值与推荐

  • 重新分级定义为Gleason评分升高和/或穿刺核心阳性比例增至34%或以上。
  • 不良病理定义为Gleason评分≥4+3和/或非器官局限性疾病(pT3或N1)。

临床怎么用

  • 前列腺癌诊断后继续使用5-ARI的患者可考虑纳入主动监测,重新分级风险未见增加。
  • 5-ARI使用者接受根治性治疗的比例较低,但需结合个体情况解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Outcomes in patients who enroll in active surveillance programs for prostate cancer while receiving 5α-reductase inhibitors have not been well defined. We sought to determine the association of 5α-reductase inhibitor use with the risk of reclassification in the PASS (Canary Prostate Active Surveillance Study). MATERIALS AND METHODS: Participants in the multicenter PASS were enrolled between 2008 and 2016. Study inclusion criteria were current or never 5α-reductase inhibitors use, Gleason score 3 + 4 or less prostate cancer at diagnosis, less than a 34% core involvement ratio at diagnosis and 1 or more surveillance biopsies. Included in study were 1,009 men, including 107 on 5α-reductase inhibitors and 902 who had never received 5α-reductase inhibitors. Reclassification was defined as increase in the Gleason score and/or an increase to 34% or greater in the ratio of biopsy cores positive for cancer. Adverse pathology at prostatectomy was defined as Gleason 4 + 3 or greater and/or nonorgan confined disease (pT3 or N1). RESULTS: On multivariable analysis there was no difference in reclassification between men who had received and those who had never received 5α-reductase inhibitors (HR 0.81, p = 0.31). Patients who had received 5α-reductase inhibitors were less likely to undergo radical prostatectomy (8% vs 18%, p = 0.01) or any definitive treatment (19% vs 24%, p = 0.04). In the 167 participants who underwent radical prostatectomy there was no suggestion of a difference in the rate of adverse pathology findings at prostatectomy between 5α-reductase inhibitor users and nonusers. CONCLUSIONS: Continued 5α-reductase inhibitor use after an initial diagnosis of prostate cancer was not associated with the risk of reclassification on active surveillance in men in the PASS cohort.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kearns JT, Faino AV, Schenk JM, et al. Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. J Urol. 2019. PMID: 30076904. doi:10.1016/j.juro.2018.07.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。